Envista (NYSE:NVST) Posts Earnings Results, Beats Expectations By $0.04 EPS

Envista (NYSE:NVST) released its earnings results on Wednesday. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04, FiscalAI reports. Envista had a return on equity of 7.88% and a net margin of 3.33%. The company had revenue of $691.50 million during the quarter, compared to analyst estimates of $688.74 million. During the same quarter in the previous year, the company posted $0.32 EPS. Envista’s revenue for the quarter was up 3.2% on a year-over-year basis.

Here are the key takeaways from Envista’s conference call:

• Envista reported 2.7% core sales growth, with adjusted EBITDA up 9% and adjusted EPS up 25%; gross and EBITDA margins expanded 20 and 80 basis points, respectively. Free cash flow conversion was 97%, and net leverage remained low at 0.6x.
• The company raised its 2026 outlook, now expecting 3.75%–4.25% core sales growth, 12.5%–14% adjusted EBITDA growth, and adjusted EPS of $1.54–$1.58. Management said the fourth-quarter outlook implies slightly negative core growth, partly reflecting four fewer selling days and continued macro uncertainty.
• China sales fell at a low-double-digit rate as orthodontics customers destocked ahead of VBP; management expects the process to bring substantial price reductions, including about 50% for orthodontics and 10%–15% for implants. It expects VBP to support volume and share gains, but acknowledged margin pressure in China.
• Spark grew at a high-single-digit rate, diagnostics and implants each grew mid-single digits, and Envista said it continued to gain share in diagnostics. Management highlighted a strong new-product pipeline and said broader commercialization of recent launches will be a key growth priority for 2027.

Envista Price Performance

Shares of NYSE:NVST traded down $2.42 during midday trading on Thursday, reaching $24.77. 3,063,586 shares of the company’s stock traded hands, compared to its average volume of 2,946,157. The company has a market cap of $3.98 billion, a P/E ratio of 42.67, a PEG ratio of 1.26 and a beta of 0.94. The company has a fifty day simple moving average of $24.49 and a two-hundred day simple moving average of $25.74. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.43. Envista has a 1 year low of $18.77 and a 1 year high of $30.42.

More Envista News

Here are the key news stories impacting Envista this week:

• Positive Sentiment: For Q3 2026, Envista reported adjusted earnings of $0.40 per share, above consensus estimates of approximately $0.35–$0.36, and revenue of $691.5 million versus expectations of about $688.7 million. EPS rose from $0.32 a year earlier. Envista tops Q3 estimates
• Positive Sentiment: Analysts’ average target price was reported at $28.86, pointing to potential upside from recent trading levels, though targets are estimates rather than guarantees. Average target price report
• Neutral Sentiment: Revenue increased 3.2% year over year, indicating growth but a measured pace. Some coverage characterized the quarter as broadly in line with expectations, despite the small beats against reported consensus figures. Q3 results coverage
• Negative Sentiment: The earnings beat was relatively small, while Envista’s reported net margin was 3.33%. Those factors may have limited enthusiasm, especially if investors were looking for stronger growth or profitability. Q3 and nine-month results

Wall Street Analysts Forecast Growth

Several brokerages recently commented on NVST. JPMorgan Chase & Co. raised shares of Envista from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $29.00 to $32.00 in a research report on Thursday, September 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Envista in a report on Tuesday. Robert W. Baird cut shares of Envista from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $34.00 to $26.00 in a research note on Thursday, October 15th. Zacks Research lowered shares of Envista from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Leerink Partners cut their target price on shares of Envista from $35.00 to $32.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. Six research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.86.

Insider Buying and Selling at Envista

In other Envista news, SVP Mischa Reis sold 8,000 shares of Envista stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total transaction of $220,000.00. Following the sale, the senior vice president owned 27,321 shares of the company’s stock, valued at $751,327.50. The trade was a 22.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is currently owned by company insiders.

Envista Company Profile

Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista’s portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.